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Abstract
During episodes of acute-inflammation high-density lipoproteins (HDL), the carrier of so-called good cholesterol,
experiences a major change in apolipoprotein composition and becomes acute-phase HDL (AP-HDL). This altered, but
physiologically important, HDL has an increased binding affinity for macrophages that is dependent on cell surface heparan
sulfate (HS). While exploring the properties of AP-HDL:HS interactions we discovered that HS caused significant remodeling
of AP-HDL. The physical nature of this change in structure and its potential importance for cholesterol efflux from
cholesterol-loaded macrophages was therefore investigated. In the presence of heparin, or HS, AP-HDL solutions at pH 5.2
became turbid within minutes. Analysis by centrifugation and gel electrophoresis indicated that AP-HDL was remodeled
generating novel lipid poor particles composed only of apolipoprotein AI, which we designate b2. This remodeling is
dependent on pH, glycosaminoglycan type, is promoted by Ca
2+ and is independent of protease or lipase activity.
Compared to HDL and AP-HDL, remodeled AP-HDL (S-HDL-SAA), containing b2 particles, demonstrated a 3-fold greater
cholesterol efflux activity from cholesterol-loaded macrophage. Because the identified conditions causing this change in AP-
HDL structure and function can exist physiologically at the surface of the macrophage, or in its endosomes, we postulate
that AP-HDL contains latent functionalities that become apparent and active when it associates with macrophage cell
surface/endosomal HS. In this way initial steps in the reverse cholesterol transport pathway are focused at sites of injury to
mobilize cholesterol from macrophages that are actively participating in the phagocytosis of damaged membranes rich in
cholesterol. The mechanism may also be of relevance to aspects of atherogenesis.
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Introduction
There is substantial evidence that high density lipoprotein
(HDL) and its major apolipoprotein, apoA-I, can inhibit the
initiation and progression of atherosclerosis [1–4]. The most
widely accepted explanation for these effects is based on HDL’s
central role in reverse cholesterol transport (RCT), the transport of
cholesterol from peripheral cells, like macrophages, to the liver for
reuse or excretion as bile acids. The HDL fraction in plasma is
composed of a polydisperse population of particles ranging from
lipid poor small discoidal pre-b-HDL, to larger lipid-rich spherical
HDL [5]. Pre-b-HDL collects cholesterol and phospholipids from
parenchymal cells and in conjunction with lecithin cholesterol
acyltransferase (LCAT), which transfers acyl groups from
phosphatidylcholine to free cholesterol, the cholesterol is convert-
ed to an ester that is retained in the core of mature spherical HDL
particles. ApoA-I is normally the most abundant protein (70–
100%) on the various classes of HDL and plays a critical role in
their functions. However, during the acute-phase response, the
initial systemic reaction to inflammation, the plasma concentration
of apoA-I declines substantially [6,7] and is replaced by serum
amyloid A (SAA), an acute-phase protein [8,9].
SAA was identified in the early 1970’s as the plasma protein
responsible forforming tissuedepositscalledamyloid (AA-type)seen
clinically in diseases with underlying persistent acute inflammation
[10,11]. Soon after its discovery, SAA was shown to be an acute-
phase protein produced by the liver within hours of tissue injury
regardless of cause. Its plasma concentration can increase a 1000-
fold (1 mg/mg to 1 mg/ml) within 24 h and return to baseline levels
over a 7–10 day period providing the tissue insult is short-lived
[12,13]. In plasma SAA is associated with HDL [13,14] and during
severe inflammation can contribute up to 80% of its apo-protein
composition [15,16]. The displaced apoA-I is rapidly cleared by the
liver and kidneys [17], and together with a sharp decline in apoA-I
gene expression during inflammation [18,19] the apoA-I plasma
half-life is reduced from 12 to 3.5 hr [6] with an overall 50–70%
reductioninplasmaconcentration [19–22].SinceapoA-Iplayssuch
an important role in RCT the apolipoprotein compositional
changes of HDL during inflammation have been viewed as being
pro-atherogenic, a conclusion that may be premature.
An ancient protein conserved from echinoderms to humans
(500–650 mya), SAA has no known homologue and until recently
no clear function [23]. Several years ago we postulated that given
SAA’s association with HDL its function must be linked to that of
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observation that SAA decreases AP-HDL’s binding affinity for
hepatocytes by 2-fold while increasing its affinity for macrophages
by up to 5-fold, and macrophages from inflamed mice have a 5-
fold increase in binding sites for AP-HDL [24–26]. The binding to
macrophage is dependent on the cell surface glycosaminoglycan,
heparan sulfate (HS) [27] and likely involves a HS binding site in
the C-terminal end of SAA [28]. Further investigations have
shown that SAA also enhances macrophage uptake of AP-HDL
[27,29–31] and once inside the cell, SAA acts to mobilize cellular
cholesterol for export [32–36]. Through the actions of two
separate domains, SAA increases neutral cholesterol ester
hydrolase (nCEH) and inhibits acyl-CoA cholesterol acyltransfer-
ase (ACAT) activities [34–36]. Intracellular cholesterol balance is
thereby shifted from cholesterol ester to free cholesterol, the form
which can be readily exported by ATP-binding cassette transport
proteins (ABCA1, ABCG1), to extra-cellular HDL acceptors [37].
Although SAA’s strong evolutionary conservation and regulated
expression implies that its function must be of significant benefit to
the host, it has been difficult to explain the survival advantage of
promoting cholesterol mobilization and efflux during a period of
apparent decline in apoA-I-based RCT potential. To address this
question we now provide the first evidence that a rapid non-
enzymatic mechanism exists for remodeling AP-HDL into apoA-I
rich particles that have enhanced cholesterol-accepting activity
complementing SAA’s function.
Results
HS causes AP-HDL to aggregate at pH 5.2
AP-HDL binding to macrophages requires cell surface HS-
proteoglycans [27] and a HSbinding site has been identified at the C-
terminus of SAA [28]. Preliminary in vitro binding assays with AP-
HDL revealed that incubation with commercially available HS,
heparin (16 kDa) or heparin3000 (3 kDa) at mildly acidic pH
(pH 5.2), caused AP-HDL to rapidly undergo a phase change and
become visibly turbid (Figure 1A).This effect didnotoccur withHDL
(Figure 1A) and was independent of protease or lipase activity. The
results were the same in the presence and absence of protease
inhibitors or EDTA (data not shown), and the effect of lipases are
reported to take several hours to influence HDL structure as opposed
to that seen with heparin, or HS, which occurs in minutes (Figure 1B).
The quantity of aggregate formed was saturable at sub-
stoichiometric concentrations of heparin or HS (approx. 10 mM
apoA-I to 4 mM heparin or HS) and reached 50% saturation in
5 min (Figure 1B). Centrifugation (10,0006g, 3 min.) produced
supernatant fractions (S-HDL-SAA) clear of aggregates and
pelleted aggregates (A-HDL-SAA) with a protein content propor-
tional to the degree of turbidity, saturating at aproximately 35% of
total AP-HDL protein content (data not shown). Aggregation was
not produced with other glycosaminoglycans, such as chondroitin
or dermatan sulfates, indicating a degree of specificity for HS and
that charge is not the only parameter of importance in this
reaction. Furthermore, aggregation was dependent on N-sulfation
of the glucosaminyl residues of heparin (Figure 1C). For HS the
addition 1 mM Ca
2+ increased turbidity a further 2-fold
(Figure 1D). Mildly acidic-pH alone did not cause any disruption
in AP-HDL structure as judged by gel filtration (not shown) and in
agreement with recent reports that HDL is a highly stable
structure [38,39].
HS remodels AP-HDL into lipid-poor apoA-I rich particles
Electrophoresis of the S-HDL-SAA fraction using non-dena-
turing PAGE revealed several new components not apparent in
untreated AP-HDL. One component was ,60 kDa (b1) and the
other ,180 kDa (b2) (Figure 2A, lane 2). Analysis of these two
bands by SDS-PAGE and tryptic mass spectrometry revealed that
the protein composition of both b1 and b2 was entirely apoA-I.
Residual SAA and other apo -proteins remained with the a-HDL
band. Re-centrifugation of the S-HDL-SAA fraction at a density of
1.25 g/ml resulted in the preferential loss of the b species
confirming their lipid poor compositions (Figure 2A, lane 3). No
increase in turbidity or obvious aggregation occurred when HDL
was incubated with heparin, although some b1 was detected on
PAGE (Figure 2B, lane 2). ApoA-I purified from HDL-SAA co-
migrated with b1 indicating that it is composed of pure delipidated
apoA-I dissociated from HDL (Figure 2B, lane 3). Delipidated
apoA-I’s (28.2 kDal) tendency to form dimers has been previously
reported [40,41].
b2-particles have exceptional cholesterol accepting
properties
The S-HDL-SAA fraction is an exceptional acceptor of
cholesterol from cholesterol-laden macrophages. Whether gener-
ated with heparin, or HS (+1m MC a
2+), the resulting S-HDL-
SAA had a 2.5 to 3-fold greater cholesterol accepting activity
relative to AP-HDL (Figure 3A). The bulk of the exported
cholesterol was derived from de-esterified cellular cholesterol esters
(Figure 3B). Analysis of S-HDL-SAA cholesterol content by thin
layer chromatography confirmed that only free-cholesterol was
accepted from cholesterol-loaded cells (data not shown). The
presence of heparin in the S-HDL-SAA fraction did not contribute
to this activity since its removal by ion exchange chromatography
had no effect on the proportion, or rate of cholesterol removed
from the cells (Figure 3C). Depletion of the b-components from
the S-HDL-SAA fraction clearly abolished its ability to promote
cholesterol efflux (Figure 3C). Heparin treated HDL also produced
some b1 but no increase in activity was evident and pure apoA-I
demonstrated poor efflux activity. These data point to the b2
species as the one playing a significant role in macrophage
cholesterol efflux.
Discussion
When macrophages take up cholesterol any excess not required
for membrane homeostasis or other functions is esterified by
ACAT and stored in ester form. These cholesterol-ester loads can
be significant for macrophages transforming them into ‘‘foam
cell’’, one of the earliest cellular indicators of atherogenesis in
arterial disease. The first step in the mobilization and export of
excess stored cholesterol via the RCT pathway is the de-
esterification of cholesterol-esters accomplished by nCEH. The
resulting free cholesterol moves through the cell membrane either
by passive diffusion or active transport by ABC transport proteins
(ie. ABCA1, ABCG1) for collection and transport by apoA-I-rich
lipoproteins.
Recent studies have demonstrated that the acute-phase protein
SAA contains two domains one of which inhibits ACAT activity
and the other enhances nCEH activity thereby substantially
shifting the balance of cellular cholesterol to that of free cholesterol
available for efflux [34–36]. Neither of these two activities is
affected by apoA-I [33–35] and since b1 and b2 described herein
consist entirely of apoA-I it is not likely that they directly promote
the de-esterification of stored cholesterol esters. Furthermore,
HDL treated with heparin generated low levels of b1, but not b2.
Although we cannot completely rule out the possibility that b1
contributed to the increase in cholesterol efflux observed for S-
HDL-SAA, its presence did not improve the efflux activity for
AP-HDL and Cholesterol Efflux
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composed of lipid free apoA-I, which was not an efficient acceptor
of cholesterol from macrophages in our assays (Figures 3A and
3B). Conversely, SAA, or its active peptide domains, can influence
ACAT and nCEH activities even in the absence of cholesterol
export but requires a cholesterol acceptor, such as HDL, for rapid
and efficient macrophage cholesterol efflux [33,35]. Efflux
promoted by SAA was demonstrated to be dependent on the
activity of ABCA1 and/or ABCG1 [34]. Moreover, we have
shown previously that the in vitro effect of AP-HDL (i.e. HDL-SAA)
on macrophage cholesterol efflux can be demonstrated in vivo [34–
36,42]. Cholesterol-laden macrophages when injected intrave-
nously into normal mice and allowed to acclimatize themselves for
24 h rapidly export their cholesterol in response to HDL-SAA, or
SAA’s active domains, in the same manner as they do in vitro. Our
present data argue that apoA-I in the form of the b2 component is
an exceptionally efficient cholesterol acceptor of exportable
cholesterol. We therefore postulate that AP-HDL contains latent
functionalities that become active when it associates with
macrophage cell surface/endosomal HS at least at sites of injury
and possibly elsewhere. The a9-component of S-HDL-SAA
contains SAA, which by virtue of its two active domains drives
Figure 1. The aggregation of AP-HDL at mildly acid pH when incubated with heparin or HS. A) HDL or AP-HDL at pH 5.2 or 7.2 were
incubated for 30 min with increasing concentrations of heparin, HS+1m MC a
2+, CS (chondroitin sufate) or DS (dermatan sulfate). The absorbance at
400 nm was then plotted against glycosaminoglycan concentration. B) AP-HDL (1 mg/ml) at pH 5.2 in 125 mM NaCl, 25 mM Na acetate, was
incubated with 0.2 mg/ml heparin and absorbance at 400 nm read at intervals to 60 min. C) AP-HDL (1 mg/ml) incubated for 20 min at 37uC with
heparin, or different chemically modified heparins, at 0.1 mg/ml as described in Panel B; CR-hep.=carboxy-reduced heparin; de-NS-hep.=N-
desulfated heparin; de-2-O-hep.=de-2-O-sulfated heparin; de-6-O-hep.=de-6-O-sulfated heparin; de-OS-hep.=de-2,6-O-sulfated heparin. D)
Incubations, supplemented with 1 mM Ca
2+, greatly increased the AP-HDL aggregation activity of HS. AP-HDL was incubated at pH 5.2 with
heparin, HS, CS, DS with or without Ca
2+, as in C). The results in C) and D) are the mean6SEM of 3 experiments. The results with CS and DS were
virtually identical.
doi:10.1371/journal.pone.0003867.g001
AP-HDL and Cholesterol Efflux
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esterification. The b2-component is the efficient extracellular
cholesterol acceptor that gets targeted to macrophages by virtue of
AP-HDL’s increased affinity and the macrophages increased
number of binding sites for AP-HDL.
The data presented herein suggests that AP-HDL on binding to
HS under mildly acidic pH associated with normal membrane
electrostatics [43,44] or endosomal compartments, can rapidly be
remodeled generating novel apoA-I-rich particles that function
physiologically to mobilize cholesterol from cholesterol-laden
macrophages at sites of tissue injury. The micro-environmental
conditions favoring HS-based remodeling of AP-HDL may occur
at sites of injury, and potentially elsewhere where macrophages are
actively scavenging damaged cell membranes. Macrophage are
exceptional at endosomal acidification reaching pH 5.0–5.5 within
10 min of endocytosis [45]. Furthermore, sites of tissue injury can
become acidic due to reduced blood supply leading to hypoxia
which forces cells to switch to anaerobic glycolysis resulting in
lactic acidosis.
We believe that the described mechanism for remodeling AP-
HDL explains why AP-HDL is consistently more effective than
HDL as a promoter of macrophage cholesterol efflux [34]
(Figure 3A). Allowing AP-HDL to interact with heparin/HS in
vitro, likely replicates, under optimum conditions, the physiological
process that takes place at the surface of the macrophage at sites of
injury. This re-modeling of AP-HDL takes place in minutes, does
not require lipases and is a natural consequence AP-HDL’s
interaction with HS likely mediated through a HS-binding site
identified on SAA [28].
As we have argued previously [8] the actions of SAA may help
conserve cholesterol pools during severe injury. The biosynthesis
of cholesterol is a significant metabolic investment requiring 30-
enzymatic steps. SAA’s influence would decrease cholesterol loss,
allow its recycling and compensate for any injury related decline of
cholesterol biosynthesis/availability that is necessary for post-
injury tissue repair. SAA’s activities may also improve the cellular
performance of macrophages at sites of injury by limiting foam cell
formation. Evidence for this latter point has recently been
provided using an experimental atherogenesis model, where the
development of aortic lipid lesions in apo-E-/- mice was effectively
prevented and even reversed by intravenous injections of
liposomal formulations of synthetic peptides corresponding to
SAA’s two functional domains [36].
Methods
Chemicals
All chemicals were reagent grade and purchased from Fisher
Scientific (Nepean, Ontario), Sigma (St. Louis, MO), ICN (Aurora,
OH), or BioRad (Hercules, CA). Dulbecco’s modified Eagle’s
medium (DMEM) and FBS were purchased from Life Technol-
ogies (Burlington, Ontario). Radiolabeled [1,2,6,7-
3H(N)] choles-
terol (82 Ci/mmol) was obtained from DuPont NEN (Boston,
MA). Glycosaminoglycans and SIGMAFAST
TM Protease Inhib-
itor were purchased from Sigma (St. Louis, MO).
Purification of HDL, AP-HDL and apoA-I
To increase plasma concentrations of SAA in CD1 mice an
acute-inflammatory state was induced by a subcutaneous injection
of 0.5 ml 2% (w/v) AgNO3 [46]. After 24 h, mice were sacrificed
by CO2 narcosis and exsanguinated by cardiac puncture
preventing clotting with EDTA. High density lipoprotein (HDL)
Figure 2. Non-denaturing polyacylamide gel electrophoresis (N-PAGE) of normal and heparin treated HDLs. AP-HDL, S-HDL-SAA and
HDL were resolved by N-PAGE using 4–20% gradient gels with a continuous buffer system consisting of 0.1 M glycine-Tris-HCl, pH 8.6. Samples
(30 mg) were loaded onto the gel and electrophoresis carried out at 4uC for 6 h at 150 volts. Bands were detected by staining with Coomassie Blue
R250. A), lane 1, AP-HDL, lane 2, S-HDL-SAA, lane 3, float sample after re-centrifugation of S-HDL-SAA at d=1.25 g/ml. Molecular weight markers are
indicated on the left; B), lane 1, HDL, lane 2, S-HDL, lane 3, delipidated apoA-I.
doi:10.1371/journal.pone.0003867.g002
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sequential density flotation [47]. The density of the plasma was
adjusted to 1.063 g/ml with NaBr and centrifuged at 175,000 g
for 18 h in a 70.1Ti rotor (Beckman) at 10uC. The top layer
containing VLDL/LDL was removed and discarded. The pooled
infranatants were adjusted to a density of 1.21 g/ml and re-
centrifuged at 250,000 g for 24–36 h at 10uC. The top layer (AP-
HDL) was aspirated, pooled, and dialysed against 20 mM Tris-
HCl, 0.15 M NaCl, 0.1% (w/v) EDTA, pH 7.5, for 18 h.
Lipoproteins were assessed by reverse phase-high pressure liquid
chromatography on a C18-Vydac column as previously described
[28]. The eluant containing apoA-I was collected, lyophilized and
stored at 220uC.
AP-HDL and HDL aggregation
Lipoproteins were applied to a Sephadex G-50 column
(1610 cm) equilibrated in 0.15 M NaCl. Void fractions were
collected and adjusted to 2 mg/ml protein, then stored on ice.
HDL or AP-HDL were diluted to a final concentration of 1 mg/
ml in 25 mM sodium acetate, 125 mM NaCl, pH 5.2 or pH 7.2
containing increasing concentrations of heparin, HS, chondroitin
sulfate (CS) or dermatan sulfate (DS). In some experiments a broad
spectrum protease inhibitor (Sigma) was included to judge the
involvement of proteolysis. Upon mixing tubes were incubated in a
water bath at 37uC for 0–60 min. Tubes were re-mixed and
absorbance read at 400 nm in a quartz cuvette (path length 1 cm).
Aggregates were collected by centrifugation at 10,0006g63 min.
Figure 3. Cholesterol efflux from J774 monocytes incubated with different lipoproteins. Monolayer cultures of J774 monocytes were
loaded with cholesterol (22.7 mg/well) and [
3H]-cholesterol (0.45 mCi) overnight, washed twice with DMEM in 0.2% BSA (1 ml) and once with DMEM
alone. Cholesterol-loaded cells were then incubated with different lipoprotein preparations (50 mg/ml) in 1 ml DMEM, 0.2% BSA; A) S-HDL-SAA
prepared with heparin; S-HDL-SAA prepared with HS+1 mM Ca2+; A-HDL-SAA; AP-HDL; HDL; S-HDL prepared with heparin. B) Lipid was extracted
from cell and analyzed by thin-layer chromatography as described previously [35] to determine the amount of [3H]-cholestryl ester remaining in the
cells relative to cholesterol-loaded cells. C) S-HDL-SAA; S-HDL-SAA preincubated with DEAE-Sepharose to remove any heparin; S-HDL-SAA
recentrifuged at 1.25 g/ml to remove lipid poor species, A-HDL-SAA and delipidated apoA-I. Aliquots of medium were taken at the time intervals
shown and the quantity of [
3H]-cholesterol exported from the cells determined and expressed as a percentage of total [
3H]-cholesterol in loaded cells
before incubations.
doi:10.1371/journal.pone.0003867.g003
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once, re-suspended in buffer and both pellet (A-HDL-SAA) and
supernatant fractions (S-HDL-SAA) were dialysed against 20 mM
HEPES, 150 mM NaCl, pH 7.2, at 4uC. S-HDL-SAA was
concentrated to 1–2 mg/ml by ultrafiltration using a Centricon
(YM10) concentrator and stored on ice until use. Heparin was
purified from some S-HDL-SAA samples by anion exchange
chromatography on DEAE-Sepharose-CL 4B column [48]. After
centrifugation to pellet the aggregates the supernatant containing
S-HDL-SAA fraction was applied to the column pre-equibrated
with 25 mM sodium acetate, 125 mM NaCl, pH 5.2 and the flow
through containing the S-HDL-SAA was collected with heparin
remaining bound to the column.
Cell culture and cholesterol loading
J774 macrophages (American Type Tissue Collection, Mana-
ssas, VA) were cultured in 6-well tissue culture plates at one million
cells per well and grown to 90% confluence in 2 ml DMEM
supplemented with 10% FBS. The medium was changed three
times a week. Cholesterol loading of cells was carried out using b-
methyl-cyclodextrin (MCD). A stock solution of 30 mM MCD in
phosphate-buffered saline (PBS) was prepared. Two ml of MCD
(30 mM) was mixed with 0.2 ml of cholesterol dissolved in ethanol
(5 mg/ml) and 20 mlo f
3H-cholesterol (20 mCi). The mixture was
incubated at 37uC for 1 h. For cholesterol loading and labeling of
the J774 cells, 50 ml of the MCD-cholesterol complex was added
to 1 ml of DMEM in 0.2% BSA overnight. After incubation, the
cells were washed twice with DMEM in 0.2% BSA (1 ml) and
once with DMEM alone prior to cholesterol efflux studies that
were carried out in DMEM-BSA.
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